The Kala Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, Data-Driven rating system and does not include human intervention.
Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Watertown, MA.
What was Kala Pharmaceuticals’s price range in the past 12 months?
Kala Pharmaceuticals lowest stock price was $4.90 and its highest was $13.84 in the past 12 months.
What is Kala Pharmaceuticals’s market cap?
Kala Pharmaceuticals’s market cap is $320.10M.
What is Kala Pharmaceuticals’s price target?
The average price target for Kala Pharmaceuticals is $23.80. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $49.00 ,the lowest forecast is $14.00. The average price target represents 316.81% Increase from the current price of $5.71.
What do analysts say about Kala Pharmaceuticals?
Kala Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
When is Kala Pharmaceuticals’s upcoming earnings report date?
Kala Pharmaceuticals’s upcoming earnings report date is Aug 11, 2021 which is next month.
How were Kala Pharmaceuticals’s earnings last quarter?
Kala Pharmaceuticals released its earnings results on May 05, 2021. The company reported -$0.493 earnings per share for the quarter, missing the consensus estimate of -$0.473 by -$0.02.
Is Kala Pharmaceuticals overvalued?
According to Wall Street analysts Kala Pharmaceuticals’s price is currently Undervalued.
Does Kala Pharmaceuticals pay dividends?
Kala Pharmaceuticals does not currently pay dividends.
What is Kala Pharmaceuticals’s EPS estimate?
Kala Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kala Pharmaceuticals have?
Kala Pharmaceuticals has 56,060,000 shares outstanding.
What happened to Kala Pharmaceuticals’s price movement after its last earnings report?
Kala Pharmaceuticals reported an EPS of -$0.493 in its last earnings report, missing expectations of -$0.473. Following the earnings report the stock price went down -18.295%.
Which hedge fund is a major shareholder of Kala Pharmaceuticals?
Among the largest hedge funds holding Kala Pharmaceuticals’s share is RA Capital Management. It holds Kala Pharmaceuticals’s shares valued at 73M.